Gender Differences in Caloric Restriction Cardioprotection
Gender Differences in Caloric Restriction Cardioprotection
批准号:
7708689
负责人:
Lin Yan
金额:
$23.4万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2011-08-31
关键词:
Adverse effectsAgeAmerican Heart AssociationAnimal ModelCaloric RestrictionCardiacCardiovascular DiseasesCatecholaminesChronicClinical TrialsEstrogensFemaleGenderGene Expression RegulationGenesGenomicsGonadal Steroid HormonesHeartHormone replacement therapyHormonesInterventionIntervention StudiesLife ExpectancyLife TablesLightLongevityMediatingMenopauseMolecularMusOutcomeOvarian hormonePostmenopausePremenopausePrevalenceProteinsProteomicsPublic HealthReportingResearchRiskSex CharacteristicsStressUnited States National Institutes of HealthWomanWomen&aposs HealthWorkage relatedbasecardiovascular risk factorinsightmalemortalitynovelpublic health relevanceresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Significant gender differences in the prevalence of cardiovascular disease have been demonstrated. The risk of developing cardiovascular disease is considerably lower in pre-menopausal females than in age-matched males, whereas after menopause, the rate of cardiovascular disease in females rises sharply. This age- dependent reversal of female cardioprotection has been attributed to the loss of circulating female sex hormones, e.g. estrogen, in post-menopausal women. Studies in animal models also provide good evidence for direct cardioprotection by estrogen. However, clinical trials including the NIH Women's Health Initiative trial have failed to demonstrate cardioprotective benefit from hormone replacement therapy (HRT) in post- menopausal women. Resolving the current disparity requires a more complete understanding of cellular and molecular mechanisms involved in gender differences in cardioprotection. CR is the most extensively studied intervention that extends longevity and protects against stress. Our preliminary studies demonstrate that under CR, females are less tolerant to chronic catecholamine stress than males. If our findings that CR is not protective in pre-menopausal females are confirmed by this study, then understanding the molecular mechanisms mediating the adverse effects in females may shed light on those mechanisms mediating the adverse outcome of HRT therapy in post-menopausal women. There are two major hypotheses: Hypothesis A: Caloric restriction protects the heart of male mice from chronic catecholamine stress, but this is not observed in female mice. Hypothesis B: Caloric restriction induces numerous differences in gene regulation in males and females, and determining those genes that mediate the adverse effects of catecholamine stress in female caloric restricted mice may provide insight into mechanisms that are protective in the presence of pre-menopausal estrogen levels. Our study will reveal novel mechanisms of gender differences in cardioprotection in caloric restriction. The implications for Public Health are clear: understanding the cardiac protective mechanisms in caloric restricted males but not in females provide the direction for the treatment of cardiovascular disease in post-menopausal women. PUBLIC HEALTH RELEVANCE: Pre-menopausal women have reduced risk for CVD, but the rate of CVD rises sharply after menopause. The loss of circulating female sex hormones, e.g. estrogen, has been suggested to contribute to this age- dependent reversal. However, clinical trials including the NIH Women's Health Initiative trial suggest that hormone replacement therapy (HRT) is ineffective in reducing, and may actually increase CVD outcomes. The current application is to investigate the gender differences in cardioprotection in caloric restriction. We have found that the intervention of caloric restriction that extends longevity and protects against stress only protects the heart of male mice from cardiac stress, but this is not observed in female mice. Understanding the molecular mechanisms mediating the adverse effects in females may shed light on those mechanisms mediating the adverse outcome of HRT therapy in post-menopausal women and provide the direction for the treatment of CVD in post-menopausal women.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Intrinsic Cardioprotection in Marmota momax
-
批准号:7842248
-
项目类别:
-
资助金额:$20.96万
-
财政年份:2009
-
负责人:Lin Yan
-
依托单位:
Gender Differences in Caloric Restriction Cardioprotection
-
批准号:7915305
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2009
-
负责人:Lin Yan
-
依托单位:
Mechanisms of Intrinsic Cardioprotection in Marmota momax
-
批准号:7849013
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2008
-
负责人:Lin Yan
-
依托单位:
Mechanisms of Intrinsic Cardioprotection in Marmota momax
-
批准号:8078143
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2008
-
负责人:Lin Yan
-
依托单位:
Mechanisms of Intrinsic Cardioprotection in Marmota momax
-
批准号:7628562
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2008
-
负责人:Lin Yan
-
依托单位:
QSTAR ELITE PRO HIGH PERFORMANCE QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETER
-
批准号:7216585
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2007
-
负责人:Lin Yan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: